Category Archives: Health

What is new in the field of Health. Trending topics, and cutting edge research in the are of Health. Press Releases that give us updates on Health.

health and fitness

Dr. Sean Doherty Now Offers Renuvion in Boston for Superior Results

Leave a comment


Renowned plastic surgeon Dr. Sean Doherty has expanded his services to include Renuvion, a cutting-edge technology that delivers remarkable skin-tightening results for those with loose or sagging skin. This revolutionary procedure is transforming the field of body contouring, offering patients a minimally invasive option for achieving smoother, tighter skin.

BOSTON, Jan. 5, 2024 /PRNewswire-PRWeb/ —

Revolutionary Renuvion Technology Arrives in Boston

Dr. Sean Doherty, a board-certified plastic surgeon based in Boston, MA, is now offering Renuvion treatments. Known for his dedication to innovative aesthetic solutions, Dr. Doherty is among the first in the Boston area to provide this advanced skin tightening procedure. Renuvion combines radiofrequency (RF) energy with helium to produce impressive skin-tightening results without the need for invasive surgery.

What Is Renuvion and How Does It Transform Body Contouring?

Renuvion employs an innovative technology that utilizes helium gas energized by radiofrequency waves to lift and tighten skin. It works beneath the skin’s surface to stimulate the body’s natural collagen production, resulting in tighter, smoother skin over time.

With Renuvion, body contouring has been revolutionized, offering patients a minimally invasive procedure for achieving their aesthetic goals. It can also be combined with other procedures, such as a facelift, neck lift, or liposuction.

The Science Behind Renuvion’s Cutting-Edge Skin Tightening

The science behind Renuvion, also known as J-Plasma, involves the utilization of a unique combination of helium plasma and radiofrequency energy.

Helium plasma, known for its precision and controlled energy delivery, is employed to gently heat the underlying tissues. This controlled heating stimulates collagen production, a vital protein responsible for skin elasticity and firmness. The addition of radiofrequency energy effectively targets and tightens the septae, which are fibrous bands situated between the skin’s surface and the muscles. The contraction of these bands leads to the smoothing of the skin’s surface, resulting in a tauter and visibly smoother appearance.

Combining Renuvion with Liposuction for Enhanced Results

Renuvion treatment may be used as a standalone procedure or in combined with liposuction. When combined with liposuction, the treatment device is inserted through the small incisions that were made for the liposuction procedure. This combination is particularly effective as it not only removes excess fat but also tightens the skin which may have become more lax after the excess fat is removed. This dual approach leads to a smoother, tighter appearance, enhancing the overall results of the body contouring procedure.

The Distinct Advantages of Renuvion Over Traditional Methods

Renuvion offers several significant advantages over traditional skin-tightening methods. Unlike surgical procedures, Renuvion is minimally invasive, reducing the risk of scarring and significantly lowering recovery time. It also works beneath the skin’s surface, treating loose or sagging skin without causing any damage to the surrounding tissues. Its cutting-edge approach stimulates the body’s collagen production, resulting in sustained skin tightening and improvement in skin quality over time.

Dr. Sean Doherty: A Leader in Aesthetic Innovation

Dr. Sean Doherty is a highly sought-after plastic surgeon renowned for his dedication to innovative aesthetic solutions. He is among the first in the Boston area to offer Renuvion treatments, demonstrating his commitment to providing his patients with the latest and most effective procedures. In addition to his surgical expertise, Dr. Doherty is a recognized leader in non-surgical procedures and a dedicated contributor to medical journals, educating his colleagues in the field.

Board-Certified Plastic Surgeon and Renuvion Expert

Dr. Doherty has been board-certified by the American Board of Plastic Surgeons for more than a decade, and his expertise extends beyond traditional surgical procedures. He is a recognized expert in Renuvion and is pleased to provide his patients with a minimally invasive option for achieving their aesthetic goals. His commitment to patient care, combined with his technical skill and innovative approach, make him a trusted choice for patients seeking superior results in body contouring and skin tightening.

Ensuring a Personalized Approach to Each Patient’s Needs

Dr. Doherty understands that every patient is unique, with distinct aesthetic goals and needs. This belief fuels the commitment to provide a tailored treatment plan that aligns with each patient’s expectations and health status. Whether you’re looking to address loose skin after weight loss or following liposuction, Dr. Doherty’s expertise in Renuvion skin tightening ensures a customized approach to your body contouring plan.

Planning Your Renuvion Procedure: What to Expect

Your journey towards a more confident self begins with a thorough consultation with Dr. Doherty. At the consultation, you can talk through your cosmetic objectives, health background, and any worries about the process. As a renowned expert in Renuvion, Dr. Doherty will provide a comprehensive overview of the process, explaining how the technology works to lift and tighten your skin.

The Renuvion procedure itself is minimally invasive and performed in his accredited surgical center with a local anesthetic. The treatment involves the use of a small probe that delivers radiofrequency energy and helium beneath the skin’s surface. Some patients will see an immediate skin contraction; however, Renuvion results are normally visible over the following months.

Following the procedure, patients can typically return to their normal activities within a week, making Renuvion a practical choice for those seeking effective results with minimal downtime.

How to Schedule Your Appointment with Dr. Doherty

Take the first step towards achieving your aesthetic goals with Dr. Sean Doherty, a leader in innovative aesthetic solutions like Renuvion. Dr. Doherty welcomes you to his state-of-the-art facility and wants to help you with enhanced confidence and self-image.

To schedule a consultation, visit the contact page for Dr. Sean Doherty or call one of his offices directly.:

Brookline Office: 1 Brookline Place, Suite 427, Brookline, MA, 02445, (617) 735-8735
Boston Office: 69 Newbury, 5th Floor, Boston, MA, 02116, (617) 450-0070

Media Contact

Amelia Viera, seandohertymd.com, 617-450-0070, [email protected], seandohertymd.com

SOURCE Dr. Sean Doherty

Health

Dr. Anthony Bared’s Mastery of Ethnic and Revision Techniques for Nasal Enhancement

Leave a comment


In the field of plastic surgery, one name stands out for its dedication to delivering natural, satisfying results – Dr. Anthony Bared. With extensive expertise in rhinoplasty, Dr. Bared utilizes his skills in the procedure and the unique aspects of ethnic and revision rhinoplasty. His mastery of these techniques has transformed lives, reshaping not just noses but confidence and self-esteem.

MIAMI, Jan. 5, 2024 /PRNewswire-PRWeb/ — Expertise in Ethnic Rhinoplasty: Respecting Cultural Aesthetics

In the field of rhinoplasty, understanding and respecting cultural aesthetics is crucial. Dr. Bared has made it his mission to offer personalized procedures that reflect and respect the unique facial features of each ethnic group. His deep understanding of ethnic characteristics allows him to create noses that are well-proportioned, natural-looking, and harmonious with each patient’s ethnicity. This expertise has made Dr. Bared a sought-after name in the field of ethnic rhinoplasty over other facial plastic surgeons.

Unique Approach to African American Rhinoplasty

African American rhinoplasty presents its own unique challenges, and Dr. Bared’s approach is nothing short of unique. Recognizing the distinct features such as wider nostrils, rounder tips, and slight, flat nasal bridges, Dr. Bared tailors each procedure to the individual.

His goal is to refine the nose’s shape while maintaining the distinct characteristics of his African American patients. Using cartilage grafts from the patient’s own body, he provides support and shape to the nasal structure, ensuring a balanced, natural-looking nose that enhances the harmony of the face.

Tailored Techniques for Asian Rhinoplasty

Asian rhinoplasty requires a different set of techniques, ones that Dr. Bared has mastered over the years. Understanding that Asian noses are typically shorter, with wide nostrils and a little-defined bridge, he focuses on augmenting the nose or improving its projection.

Whether it’s enhancing the nasal bridge, strengthening the nasal tip, or enlarging the nose, Dr. Bared’s procedures are carefully personalized to preserve the patient’s unique heritage. His use of computer imaging during consultations offers patients a glimpse of the transformation, instilling them with confidence and excitement about the outcome.

Navigating the Complexities of Revision Rhinoplasty

Revision rhinoplasty is a procedure that calls for a surgeon with substantial experience and sophisticated knowledge. It’s designed to rectify past imperfections and bring patients closer to their ideal nose shape. Dr. Bared’s approach to revision rhinoplasty is to address the root issues rather than merely camouflaging the problem, providing truly transformative results.

The Art and Precision of Corrective Nasal Surgery

Corrective nasal surgery is a blend of artistry and precision. Dr. Bared’s method for revision rhinoplasty incorporates the utilization of the patient’s natural cartilage instead of artificial implants, removing the necessity for synthetic implants.

Depending on the deformity, the cartilage used for grafts can come from the septum, ear, or rib. This surgical technique helps the nose keep its new aesthetic appearance after surgery by allowing it to withstand the tightening of the overlying skin. The procedure is performed under general anesthesia, and the use of fine sutures to close the incisions leaves a minimal, barely visible scar.

Emphasizing Natural Results in Nasal Enhancement

Dr. Bared’s emphasis on natural results in nasal enhancement sets him apart in the field. His approach to both primary and revision rhinoplasty involves creating a sturdy base structure to support the nose long-term. His goal is to provide a balanced, natural-looking nose that enhances the harmony of the face without losing the patient’s unique ethnic characteristics. Dr. Bared’s commitment to delivering natural results is reflected in his meticulous surgical planning and the careful execution of each procedure.

Balancing Aesthetics and Functionality in Rhinoplasty

Rhinoplasty isn’t just about aesthetics (also called cosmetic rhinoplasty) – It’s also about functionality.

Rhinoplasty, done well, can enhance facial balance and resolve breathing problems, providing lasting benefits for the patient’s comfort and well-being. Dr. Bared understands the importance of balancing aesthetics and functionality in rhinoplasty.

Whether it’s correcting a crooked nose, a collapsed nasal septum, or a broken nose, Dr. Bared ensures that the procedure not only improves the patient’s appearance but also enhances their quality of life. His expertise in revision rhinoplasty enables him to address both cosmetic and functional nasal concerns while respecting the patient’s unique heritage.

Dr. Bared’s Commitment to Patient-Centered Care

At the heart of Dr. Bared’s practice is a deep commitment to patient-centered care. Recognizing that each patient is unique, he ensures that every procedure he performs caters to the individual’s needs and aesthetic goals.

Beyond achieving beautiful, natural-looking results, Dr. Bared is also committed to ensuring that his patients feel comfortable and well-informed after their nose surgery. This commitment extends to all aspects of his practice, from the initial consultation to the careful execution of each procedure and the comprehensive aftercare provided.

Personalized Consultations Using Advanced Imaging

Dr. Bared believes in the importance of clear communication and shared understanding with his patients. During personalized consultations, he listens attentively to the patient’s concerns and goals, performs a thorough evaluation of the nose, and discusses the potential outcomes of the procedure.

To help patients visualize the possible results, Dr. Bared uses advanced computer imaging. This technology allows patients to see a realistic simulation of their post-surgery appearance, instilling them with confidence and excitement about the transformation ahead. This approach ensures that patients are fully informed and comfortable with their decision, fostering a strong sense of trust and partnership.

Contact Dr. Bared for a Rhinoplasty Consultation in Miami

If you’re considering a primary rhinoplasty, a revision procedure, or an ethnic rhinoplasty, Dr. Bared’s expertise and commitment to patient care make him a trusted choice.

Dr. Bared’s practice, with a focus on rhinoplasty, hair restoration (including beard transplants), and revision rhinoplasty procedures, comprises over 70% of his work, ensuring his proficiency and experience in delivering outcomes that align with your plastic surgery aspirations and standards.

Contact Dr. Bared’s office to set up a consultation by calling 305-359-7299 or filling out a contact form to start your journey towards enhanced confidence and well-being.

The practice is located at 6280 Sunset Dr. #506, Miami, FL 33143.

Media Contact

Amelia Viera, facialplasticsurgerymiami.com, (305) 359-7299, [email protected], facialplasticsurgerymiami.com

SOURCE Dr. Anthony Bared

health and fitness

Credo Health Announces Oversubscribed $5.25 Million Series Seed Funding

Leave a comment


This substantial investment reinforces Credo Health’s mission to build the definitive platform for value-based care providers. Its core platform, PreDx, provides the complete clinical picture for every patient while supporting risk adjustment, quality and health equity.

“This investment is a testament to our commitment to fully support providers with the technology they need to succeed in value based care,” said Credo Founder and CEO Carm Huntress, expressing his excitement about the growth they’ve seen in PreDx since launching at the Vive Conference in March just 9 months ago. “It’s clear that value based care providers need a technology partner that not only empowers providers to deliver the highest quality patient care, but also one that ensures accurate, up to date risk adjustment and quality information that meets the latest regulatory guidelines.”

Credo Health’s forward momentum extends through strategic partnerships, including its recent collaboration with Vim, a middleware platform for healthcare that unlocks access to provider Electronic Health Record (EHR) workflow. This partnership enhances EHR workflow integration with AI-powered medical retrieval and analysis, connecting providers and patients for improved healthcare outcomes.

“We’ve been looking deeply at technology across the value based care market and it was clear to us the team and technology were far superior to anything else we evaluated. We could not be more excited about our investment in Credo and the timing as we continue to see significant growth in value based care,” said Tom Hearn, Partner at FCA Venture Partners and now Credo board member.

Currently working with leading value-based care organizations, Credo Health’s PreDx product has yielded impressive results, with organizations achieving much more accurate risk adjustment and quality scores while supporting higher quality care and patient satisfaction scores. These funds will further strengthen Credo’s technological infrastructure, expand its sales team and continue driving innovation within the value based care market.

Credo will be attending the JP Morgan Annual Healthcare Conference and is excited to meet with top VBC providers, payers and investors.

About Credo: Credo Health’s PreDx product offers a pre-encounter risk analysis, clinical summaries and HEDIS Gap Closure through an AI-enabled analysis of digital medical records, allowing healthcare providers to make more informed clinical decisions and deliver more personalized care. Through its innovative solutions, Credo is transforming healthcare, facilitating better decision-making, and driving meaningful progress in the industry. For more information, visit credohealth.com.

About FCA Venture Partners: FCA Venture Partners is a venture capital firm investing in early-stage healthcare technology and technology-enabled healthcare services companies that improve patient care, reduce costs, or increase efficiency. FCA manages over $225 million and invests across the Series Seed to Series B stages. FCA brings portfolio companies valuable healthcare insights, connections, and board-level experience to accelerate growth and build disruptive and sustainable businesses. Based in Nashville, the epicenter of healthcare innovation, and Charlotte, the FCA team has a decades-long track record including more than 60 investments in the rapidly changing healthcare industry.

Media Contact

Carm Huntress, Credo Health, 1 720-352-2276, [email protected], https://www.credohealth.com/

SOURCE Credo Health

Health: Abortion

JDASC requests SEC Chairman Gary Gensler to acknowledge 21 million bitcoin hard cap is not guaranteed before approving bitcoin ETFs

Leave a comment


Deters continued, “Not having an absolute bitcoin supply cap of 21 million bitcoins is not necessarily a “bad thing”. Instead it could potentially be exploited to increase bitcoin market penetration. In one scenario, if the bitcoin price was to hit $100,000, bitcoin‘s ecosystem, including miners, full node validators and the bitcoin core maintainers could all agreed to implement a 1000 to 1 bitcoin split, similar in nature to a stock split. The BIP proposed implementation would go out to the entire bitcoin consensus voting base. If accepted, instead of 100,000,000 Satoshi per bitcoin, there would be 100,000. Every bitcoin wallet address balance would be increased by 1000x. The most important aspect to this imagined BIP implementation is reducing the bitcoin cost from $100,000 to $100. At such a low price, it could easily result in a tsunami wave of new retail bitcoin buyers. This would be initiated by the fact investors prefer to own “full shares” in an enterprise and not “fractional shares”. In this example, a full share is one bitcoin, one Satoshi is the “fractional share”.

Deters further stated, “Another scenario could involve a BIP which increases per block mining reward from the current 6.25 bitcoins to the original 50 bitcoins. Every bitcoin address balance would be increased based on the mining reward percentage increase. Another and not out of the realm of possibility worst case scenario could involve the next generation after GenAlpha. A generation that may quite possibly become outraged with the severe consequences of global warming, out of control consumerism and massive disproportionate global wealth distribution. This generation may not want to support a financial system such as bitcoin in which currently 90% of the wealth and supply is controlled by less than 10% of bitcoin owners. In this scenario, a scorch and burn effort to destroy the bitcoin blockchain could quickly gain global momentum. This could easily be fueled by an underlying resentment of bitcoin billionaire investors who gained an insane amount of wealth without contributing anything back to society or the planet. This possible scenario could feasibly become a worldwide political and social justice rallying call for a financial revolution, ironically for the same reason why bitcoin was originally created”.

Deters concluded, “I am not predicting or encouraging any of the described BIP acceptance scenarios, only that those and other potential bitcoin blockchain BIP scenarios are all possible. As the founder of JDASC, a public benefit and consumer protection corporation, I am simply performing my fiduciary duties. JDASC has a responsibility to protect potential consumer bitcoin ETF investors by ensuring all facts are presented and all miss representations are exposed, This responsibility includes presenting both best case and worst case potential investment scenarios as well.

Media Contact

John Deters, JDASC, 7702382085, [email protected], In process

SOURCE JDASC

Health

Evalueserve Secures Consecutive Win in 2024 Chartis RiskTech100®

Leave a comment


Chartis Research named Evalueserve the winner of the “Model Validation – Supporting Tools” category for the second year in a row.

ZUG, Switzerland, Jan. 5, 2024 /PRNewswire-PRWeb/ — Evalueserve, a pioneer in analytics and risk management solutions, announced today that it won the “Model Validation – Supporting Tools” category in the prestigious RiskTech100® 2024 awards. This accolade, which Evalueserve has now won two years in a row, reinforces Evalueserve’s status as a vanguard in risk technology, continually demonstrating an exceptional combination of skilled services and innovative technology.

The RiskTech100® is a flagship report of Chartis Research, an independent analyst firm known for its detailed assessment of key players in risk and compliance technology. This annual report ranks top companies in these sectors using a well-established and thorough methodology.

Evalueserve’s Model Validation Accelerators exemplify its dedication to driving innovation forward in finance and include:

  • Automated model test interpretation and documentation to simplify validation.
  • AI/ML challenger model development to bolster robustness and precision.
  • Extensive pricing libraries for a broad spectrum of financial instruments.
  • Advanced workflow platform to boost both efficiency and governance.

Evalueserve’s risk management prowess is built on the expertise of over 500 professionals experienced across various financial models, asset types, and regulatory environments. The company’s growth is fueled by seasoned experts with strong ties to major financial institutions and a commitment to advancing their specialization. Combining this deep domain knowledge with expertise in risk data and analytics, Evalueserve develops cutting-edge AI and automation tools to optimize and scale risk management operations.

“Being recognized by Chartis Research for our model validation accelerators for two consecutive years is a tremendous honor,” said Anna Slodka-Turner, Evalueserve’s Global Head of Risk and Quant Solutions. “Our deep domain expertise, which covers a range of both internal and vendor models, and experience across various major regulations, including the recent SS 1/23, enable us to understand and address the critical pain points of risk teams, automating processes specifically tailored to their needs.”

The RiskTech100® 2024 recognition is a hallmark of Evalueserve’s dedication to advancing risk technology. Looking ahead, Evalueserve remains committed to innovating solutions that are developed by practitioners for practitioners, ensuring that their clients are equipped for the evolving landscape of risk management.

To access the Chartis RiskTech100® report and learn more, visit www.chartis-research.com/risk-data-technologies/7947011/risktech100r-2024.

About Evalueserve

Evalueserve is a global leader in technology-enhanced managed services. Combining the strengths of best-in-class AI and a team of over 4,500 experts, the company focuses on data and analytics, competitive and market intelligence, and IP and R&D services. Evalueserve provides tailored, innovative solutions for each client, ensuring efficiency and return on investment. Learn more at evalueserve.com.

Contact Us
For more information on Evalueserve’s sustainability initiatives or to request an interview, please contact Renuka at [email protected].

Media Contact
Renuka, Evalueserve, 1 9192014003, [email protected], https://www.evalueserve.com/

SOURCE Evalueserve

health and fitness

AI-Powered Weight Loss Takes Center Stage as EW2Health Unveils Game-Changing Sinque Technology

Leave a comment


Sinque benefits weight loss professionals, corporate wellness, health insurance, preventive medicine, and health innovators. The Sinque patented algorithm uses predictive behavioral analytics to learn a user’s weight fluctuation patterns and predict their ‘true’ weight trend. Health professionals use the Sinque technology dashboard to assess individual and group metrics and to gauge adherence, weight trends and weight loss results. They see quickly who is on track and who needs more attention, eliminating blind spots between appointments. For the first time, professionals can provide truly personalized healthcare in the form of proactive, tailored support based on data and individual needs.

Patients of health professionals using Sinque track their progress via the Sinque app and a numberless monitor, which eliminates frustrations with the ups and downs on the scale. Combined, the Sinque tools result in a more successful, sustainable weight-loss journey. Sinque trials demonstrate that combining AI-driven data for health professionals with stress-free user monitoring significantly lowers dropout rates, improves results, and reduces health professionals’ management time.

“An individual’s weight naturally fluctuates up to 6.6 pounds (3 kilos) per day — from hydration, medication, time of day, and dozens of other causes — which routinely leads people to draw the wrong conclusions from the scale,” said EW2Health’s CTO and founder Renato Romani, M.D. “This is a main cause of the 80% attrition rate we see in weight loss programs. Conversely, Sinque users see their accurate weight trend, receive proactive support from their health professional, and are excited and empowered to stay on track.”

Benefits of Sinque include:

  • Stress-free, numberless monitoring, with weight trend that motivates adherence;
  • Data-driven, proactive, personalized support, even between appointments; and
  • Increased Customer Lifetime Value (CLV), reduced management time and increased program efficiency.

“The results of our trials are groundbreaking,” added J’Amy Stewart, EW2Health CEO and co-founder. “In a recent six-month workplace wellness pilot program with the largest corporation in South America, 25% of participants reduced their BMI, 10% lost ≥10% of their body weight, and the program had an 89% retention rate — more than quadruple the industry average. This is a game-changer for long-term weight loss results, especially in tandem with new obesity drugs like Ozempic and Mounjaro.”

Interested media, industry partners and investors are invited to contact [email protected] to set up a meeting in Las Vegas at CES 2024, January 9–12, 2024. Access the press kit here.

About EW2Health

EW2Health BV is a pioneering Dutch technology startup with friendly, data-driven solutions that enable personalized health using AI-based predictive behavioral analytics. EW2Health’s first goal is to reverse the global obesity epidemic and significantly reduce associated healthcare costs through effective personalized healthcare. Founded in 2018, EW2Health is a privately held company headquartered in The Hague. Follow EW2Health on LinkedIn or learn more at www.easywaytohealth.com.

Media Contact

J’Amy Stewart, EW2Health, 31 6-2513-1198, [email protected], www.easywaytohealth.com 

Renato Romani, EW2Health, 31 6-1248-3753, [email protected], www.easywaytohealth.com 

LinkedIn

SOURCE EW2Health

Health

Mercaptor Introduces Powerful CAPTON™️ Platform for Precision Neurology

Leave a comment


New Technology Addresses Brain Trauma Including Alzheimer’s, TBI, and Epilepsy

SAN FRANCISCO, Jan. 5, 2024 /PRNewswire-PRWeb/ — Mercaptor Inc, a privately held pharmaceutical company, today announced a breakthrough platform for the CNS. The pivotal technology overcomes challenges that have limited the development of meaningful treatments for the brain. The chemistry improves distribution, proportionates drug activity based on pathology in situ, and limits drug exposure to those areas of the brain suffering pathogenic stress. The unique chemistry behind the approach involves substituting an essential sulfonate group on suitably-configured drugs with an activity-disqualifying thiol, yielding a small molecular therapeutic, termed Capton. Structure-Activity Relationship (SAR) is sufficiently understood for the development of a broad class of therapeutics targeting key disease mechanisms. Mercaptor’s CNS CAPTON platform promises to meaningfully impact the treatment of brain disease and damage worldwide.

Patients suffering from neurodegeneration, including Alzheimer’s, Parkinson’s, and Huntington’s disease, as well as those subjected to brain trauma, including epilepsy, stroke, and TBI, have had little recourse to therapeutic intervention. These largely unaddressed conditions share complex etiologies and limited pharmacological accessibility. Mercaptor recognizes the need for potent, precisely-regulated, therapeutics in the clinic. A discovery by Mercaptor’s team led to a new class of prodrugs, Captons, which are effectuated by sulfur-redox chemistry catalyzed by physiologically relevant transition metal ions. Such chemistry can be readily detected in the body, but only in areas of the CNS suffering from a variety of insults, including neurodegeneration and trauma.

Studies by Mercaptor’s scientists have demonstrated that these prodrugs, administered orally, become active only in the CNS, specifically in those areas where unchaperoned redox-active metal ions and ROS have reached pathogenic levels. Both species are strongly associated with most neuropathological conditions. Redox chemistry of this variety is a unique feature of the interstitium of the brain, where levels of albumin are a fraction of those found everywhere else in the body.

Building on knowledge gathered by countless researchers over many decades in the fields of sulfur chemistry and oxidative stress biology, Mercaptor’s CAPTON platform provides the means to practice precision neurology with exquisite control over the location and dose of a variety of therapeutics. Our candidate pool consists of well-documented therapeutics acting locally to enhance GABA and taurine activity or to engage P2Y12R, AGTR1, CD40L, SHP2, PIK3CB, VGLUT, ACP1 and the S1P receptors.

“Working with this platform has been the experience of a lifetime for us. It is the sort of technological leap forward that can change how therapies for the CNS are conceived and developed,” said Dr. Todd Zankel, Chief Scientific Officer of Mercaptor. “The recent advent of AI will provide another boost to such efforts. Given the defined SAR behind our approach, we expect that AI will allow a more thorough and efficient exploration of chemical space, accelerating the identification of promising drug candidates and streamlining the development process.”

“We are driven by a commitment to advance the field of neurodegenerative disease and deliver breakthrough therapies,” said Sara Isbell, CEO of Mercaptor. “Our CAPTON platform represents a revolutionary stride in shaping disease-modifying therapies for neurology. From combating brain degeneration to shielding against the perils of cosmic radiation during extended space travel, its applications span an astonishing breadth. The sheer versatility of CAPTON technology, from therapeutics to space exploration, underscores the remarkable and unexpected potential this innovation brings to the forefront.”

Through strategic partnerships with leading research organizations and industry leaders, Mercaptor aims to accelerate the development and commercialization of its groundbreaking CAPTON technology.

About Mercaptor Inc:

Mercaptor is a privately held clinical-stage pharmaceutical company focused on revolutionizing drug discovery and development for neurodegenerative diseases and trauma.

For media and investor inquiries, please contact:

Sara Isbell

CEO, Co-founder

1 (628) 280-9327

[email protected]

SOURCE Mercaptor Inc

Lifestyle: Self Help

Martin Searle Solicitors launch their new campaign “Menopause Matters” in January 2024 to stamp out Menopause Discrimination in the Workplace

Leave a comment


Although the menopause is not specifically identified as a type of discrimination under the Equality Act, the Employment Law Team at Martin Searle Solicitors are seeing a number of employees with menopausal symptoms experiencing disability discrimination, age discrimination and / or sex discrimination at work.

Many workplaces do not adequately support their staff who are going through the menopause. A 2022 report by the Fawcett Society reported that 80% of women said that their employer did not have a menopause policy in place or offered any training to staff around the menopause. Sadly, one in ten menopausal women have left their job due to their symptoms.

Fiona Martin, Director and Head of Employment Law at Martin Searle Solicitors, said “We have spoken to many employees who believe they have been unfairly selected for redundancy or discriminated against because they are going through the menopause. We are a campaigning law firm who educate employers to be supportive and to follow best practice on this issue. We also support employees who are being discriminated against. We want to make menopause discrimination a thing of the past and encourage employers to be aware of the issues and to make reasonable adjustments where necessary.”

Their campaign includes a free virtual seminar for employee advisers and trade union representatives on Menopause Discrimination At Work on Thursday 25 January 2024, and a virtual seminar for charities and non-profit organisations on Menopause Discrimination – Best Practice for Employers on Tuesday 30 January 2024. They are also providing a free menopause policy for organisations.

Martin Searle Solicitors Employment Law Team are also providing a free 30 minute confidential advice line for employers, employees and workers on the rights of staff going through the menopause and employer duties to support employees and workers. Employers, employees and workers can call 01273 609911 from 3.30pm – 5.30pm on Tuesdays and Thursdays throughout January 2024.

For more information, please visit www.ms-solicitors.co.uk/menopause-matters

Media Contact

Chris Parkinson, Martin Searle Solicitors, 44 1273609911, [email protected], https://www.ms-solicitors.co.uk

SOURCE Martin Searle Solicitors

Health: Addiction

Veterans Exploring Treatment Solutions (VETS) Grant Recipients Participate in Groundbreaking Stanford Study on Ibogaine Treatment for PTSD and TBI

Leave a comment


First-ever study of ibogaine treatment for TBI reveals reduced symptoms and improved functioning

CORONADO, Calif., Jan. 5, 2024 /PRNewswire-PRWeb/ — Veterans Exploring Treatment Solutions (VETS), a leading non-profit organization dedicated to ending veteran suicide, shares the findings of a new groundbreaking study that it supported alongside Stanford University. The study, published today in Nature Medicine, is the first-of-its-kind observational study that captured the effects of ibogaine, the plant-based psychoactive drug, on veterans with Traumatic Brain Injury (TBI) and the debilitating consequences, including Post Traumatic Stress Disorder (PTSD).

The study demonstrated that prior to ibogaine treatment, participants scored an average of 30.2 on the World Health Organization Disability Assessment Schedule 2.0, equivalent to mild to moderate disability. At one month following ibogaine treatment, the average rating improved to 5.1, equivalent to no disability. The researchers also found a statistically significant reduction in suicidal ideation from participants, decreasing from 47% to 7% one month following treatment. The participants experienced no serious side effects or heart complications resulting from the ibogaine treatment.

The paper, authored by Dr. Nolan Williams, Associate Professor in the Department of Psychiatry and Behavioral Sciences and the Director of the Brain Stimulation Lab at Stanford University, indicates that ibogaine, combined with a cardioprotective agent, effectively treated TBI in Special Operations veterans. Researchers enrolled 30 U.S. Special Operations veterans in the study, all of whom had received Foundational Healing Grants from VETS for travel support and ibogaine therapy. The study revealed that ibogaine therapy significantly reduced PTSD, anxiety, depression, and improved cognitive function in veterans with TBI.

“Veterans are on the front line of our national defense, but here they are on the front line of cutting-edge research that has the potential to help millions of people – both in and out of uniform,” said Amber Capone, Co-Founder and CEO of VETS. “We remain laser-focused and dedicated to our mission of supporting access to psychedelic-assisted therapies for veterans and advancing research into their safety and efficacy. Our collaboration with Stanford University and Dr. Williams is a major step forward in proving the potential of ibogaine for treating PTSD and TBI.”

Since its inception in 2019, VETS has been at the forefront of combating veteran suicide by providing resources, research, and advocacy efforts for veterans and veteran spouses seeking psychedelic-assisted therapies for PTSD, TBI, and other mental health conditions. The 30 participants selected had a history of TBI and repeated blast exposures and were experiencing clinically severe psychiatric and cognitive impairments before seeking support from VETS. The participants had significantly improved, both psychiatrically and cognitively, persisting at least one month after treatment, the endpoint of the study.

“I went from being constantly angry and feeling alone, burdened by the trauma of war and the loss of 12 friends to suicide, to finding a renewed sense of hope and peace,” said Patrick Flatley, a U.S. Army Green Beret veteran and study participant. “The turning point was ibogaine treatment. Today, I am grateful to sleep well, live without daily fight or flight reactions, and look forward to life with newfound hope.”

“This reinforces what we’ve learned through thousands of treatments, that ibogaine can be safe and effective when provided in the right context. For Ambio, the study further highlights the remarkable healing potential of ibogaine, which we’re confident will expand the treatment landscape for veterans and many others,” said Jonathan Dickinson, Ambio’s CEO.

All participants in the study received treatment at Ambio Life Sciences, an independent clinic in Mexico that provides somatic therapies alongside psychedelic therapies in a medically supported environment. VETS provided travel funding for the study participants as part of its Foundational Healing Grants program, along with classes, coaching, integration support, and more. VETS does not provide psychedelic-assisted therapy.

About VETS

Founded in 2019, Veterans Exploring Treatment Solutions (VETS) is a 501(c)(3) non-profit organization working to end the veteran suicide epidemic by providing resources, research, and advocacy for U.S. military veterans seeking psychedelic-assisted therapies for traumatic brain injury (TBI), post-traumatic stress disorder (PTSD), addiction, and other health conditions. VETS envisions a world where our veterans have access to the most advanced healthcare options to heal from the mental and physical wounds of war.

Media Contact

Brad Burge, Veterans Exploring Treatment Solutions (VETS), 1 (650)-863-6887, [email protected], vetsolutions.org 

SOURCE Veterans Exploring Treatment Solutions (VETS)

Health: Abortion

Seay Felton Trial Lawyers’ Heartwarming 2023 and Festive Start to 2024

Leave a comment


Seay Felton Trial Lawyers’ Heartwarming 2023 and Festive Start to 2024: Making a Difference in the Community and Beyond

MACON, Ga., Jan. 4, 2024 /PRNewswire-PRWeb/ — Seay Felton Trial Lawyers, a prominent legal firm known for their commitment to justice, compassion, and community engagement, celebrated a memorable December 2023 with two events that embodied the spirit of giving.

In early December, Seay Felton Trial Lawyers actively joined the “12 Days of Giving” campaign, a gratifying initiative that unfolded in Macon, Georgia. This charitable endeavor was hosted by WMGT 41, a local news station, and exemplified the essence of the holiday spirit. In a testament to the firm’s generosity, Seay Felton Trial Lawyers distributed two gift cards, each valued at $250. These gift cards symbolize more than just generosity; they represent the firm’s commitment to supporting and uplifting the community.

In addition to the “12 Days of Giving,” Seay Felton Trial Lawyers partnered with Mount Vernon Baptist Church to organize a Coat Drive throughout December. As the winter season arrived, the firm stepped up to assist those less fortunate in Atlanta.

We understand the significance of staying warm in the colder months and extend our gratitude to these organizations for affording us the chance to positively influence the lives of individuals and families within our community.

As we enter 2024, Seay Felton Trial Lawyers remain unwavering in their commitment to the community. While the official holiday season has concluded, the spirit of giving persists. The events of December 2023 underscored the firm’s dedicated service to Macon, Atlanta, and its residents, demonstrating that kindness knows no seasonal boundaries.

For more information about Seay Felton Trial Lawyers and their dedication to personal injury cases, please visit http://www.sftriallawyers.com.

About Seay Felton Trial Lawyers:

Seay Felton Trial Lawyers is an experienced personal injury law firm serving the Atlanta and Macon, GA areas. With a proven record of success and a commitment to securing fair compensation for our clients, our attorneys offer unparalleled expertise and innovative legal solutions. We go beyond conventional legal approaches, uncovering new opportunities to ensure our clients receive the restitution they deserve.

Media Contact

Daniela Arroyave, Exults, 866-999-4736, daniela.arroyave@exults.com, https://www.exults.com/

SOURCE Seay Felton Trial Lawyers